Marta Guzmán

7.9k total citations · 3 hit papers
31 papers, 4.4k citations indexed

About

Marta Guzmán is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Marta Guzmán has authored 31 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 13 papers in Molecular Biology and 12 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Marta Guzmán's work include HER2/EGFR in Cancer Research (15 papers), Monoclonal and Polyclonal Antibodies Research (12 papers) and PI3K/AKT/mTOR signaling in cancer (10 papers). Marta Guzmán is often cited by papers focused on HER2/EGFR in Cancer Research (15 papers), Monoclonal and Polyclonal Antibodies Research (12 papers) and PI3K/AKT/mTOR signaling in cancer (10 papers). Marta Guzmán collaborates with scholars based in Spain, United States and Palestinian Territory. Marta Guzmán's co-authors include Maurizio Scaltriti, Joaquı́n Arribas, José Baselga, Violeta Serra, Federico Rojo, Serena Di Cosimo, José Baselga, Pieter J.A. Eichhorn, Santiago Ramón y Cajal and Javier Cortés and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Marta Guzmán

30 papers receiving 4.3k citations

Hit Papers

Expression of p95HER2, a Truncated Form of the HER2 Recep... 2007 2026 2013 2019 2007 2008 2016 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer
    2007 659 citations Maurizio Scaltriti, Federico Rojo et al. JNCI Journal of the National Cancer Institute profile →
  2. NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
    2008 626 citations Violeta Serra, Ben Markman et al. Cancer Research profile →
  3. Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer
    2016 511 citations María Teresa Herrera-Abreu, Marta Palafox et al. Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marta Guzmán Spain 17 2.8k 2.2k 1.3k 1.1k 589 31 4.4k
Youngchul Song United States 13 3.0k 1.1× 3.0k 1.3× 2.7k 2.0× 510 0.5× 908 1.5× 18 5.5k
Teemu T. Junttila Finland 24 2.4k 0.9× 1.6k 0.7× 740 0.6× 1.6k 1.5× 277 0.5× 32 3.7k
Bassam Abdulkarim Canada 32 1.2k 0.4× 1.3k 0.6× 878 0.7× 778 0.7× 1.2k 2.0× 98 3.7k
Marzia Capelletti United States 27 2.9k 1.0× 2.5k 1.1× 2.6k 2.0× 642 0.6× 816 1.4× 66 5.2k
Violeta Sánchez United States 28 2.1k 0.7× 2.1k 1.0× 661 0.5× 566 0.5× 840 1.4× 59 3.8k
Muralidhar Beeram United States 27 1.7k 0.6× 1.3k 0.6× 835 0.6× 616 0.6× 380 0.6× 89 3.0k
Cammie Rinehart United States 15 1.7k 0.6× 1.7k 0.8× 567 0.4× 719 0.7× 327 0.6× 19 2.8k
Stacy L. Moulder United States 32 2.5k 0.9× 1.4k 0.6× 922 0.7× 589 0.5× 1.3k 2.1× 141 3.9k
Judy Dering United States 23 2.2k 0.8× 1.5k 0.7× 1.3k 1.0× 238 0.2× 902 1.5× 41 3.6k
Ludmila Prudkin United States 23 1.9k 0.7× 1.7k 0.8× 804 0.6× 522 0.5× 1.5k 2.6× 50 3.8k

Countries citing papers authored by Marta Guzmán

Since Specialization
Citations

This map shows the geographic impact of Marta Guzmán's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marta Guzmán with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marta Guzmán more than expected).

Fields of papers citing papers by Marta Guzmán

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marta Guzmán. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marta Guzmán. The network helps show where Marta Guzmán may publish in the future.

Co-authorship network of co-authors of Marta Guzmán

This figure shows the co-authorship network connecting the top 25 collaborators of Marta Guzmán. A scholar is included among the top collaborators of Marta Guzmán based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marta Guzmán. Marta Guzmán is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Munárriz, Pablo M., et al.. (2025). Impact of the COVID-19 pandemic on the incidence of pediatric intracranial empyemas in Spain. Child s Nervous System. 41(1). 107–107.
2.
Palafox, Marta, Touati Benoukraf, Patrick Jaynes, et al.. (2018). Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies. The Journal of Experimental Medicine. 215(7). 1913–1928. 44 indexed citations
3.
Herrera-Abreu, María Teresa, Marta Palafox, Uzma Asghar, et al.. (2016). Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer. Cancer Research. 76(8). 2301–2313. 511 indexed citations breakdown →
4.
García-García, Celina, Yasir H. Ibrahim, Violeta Serra, et al.. (2012). Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy. Clinical Cancer Research. 18(9). 2603–2612. 118 indexed citations
5.
Scaltriti, Maurizio, Pieter J.A. Eichhorn, Javier Cortés, et al.. (2011). Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 + breast cancer patients. Proceedings of the National Academy of Sciences. 108(9). 3761–3766. 251 indexed citations
6.
Serra, Violeta, Maurizio Scaltriti, Ludmila Prudkin, et al.. (2011). PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene. 30(22). 2547–2557. 433 indexed citations
7.
Scaltriti, Maurizio, Violeta Serra, Emmanuel Normant, et al.. (2011). Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer. Molecular Cancer Therapeutics. 10(5). 817–824. 44 indexed citations
8.
García-García, Celina, Violeta Serra, Maurizio Scaltriti, et al.. (2011). Abstract 653: Combination of TORC1/2 and MEK kinase inhibitors in colorectal cancer models. Cancer Research. 71(8_Supplement). 653–653. 1 indexed citations
9.
Scaltriti, Maurizio, Sarat Chandarlapaty, Ludmila Prudkin, et al.. (2010). Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2–Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor. Clinical Cancer Research. 16(9). 2688–2695. 114 indexed citations
10.
Russillo, Michelangelo, Maurizio Scaltriti, Olga Rodríguez, et al.. (2010). Abstract 4477: Dual-targeting of AMPK and PI3K/mTOR in a panel of breast cancer cell lines. Cancer Research. 70(8_Supplement). 4477–4477. 1 indexed citations
11.
Chandarlapaty, Sarat, Maurizio Scaltriti, Qing Ye, et al.. (2009). Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Oncogene. 29(3). 325–334. 99 indexed citations
12.
Serra, Violeta, Ben Markman, Maurizio Scaltriti, et al.. (2008). NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations. Cancer Research. 68(19). 8022–8030. 626 indexed citations breakdown →
13.
Eichhorn, Pieter J.A., Magüi Gili, Maurizio Scaltriti, et al.. (2008). Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235. Cancer Research. 68(22). 9221–9230. 378 indexed citations
14.
Scaltriti, Maurizio, Chandra Verma, Marta Guzmán, et al.. (2008). Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene. 28(6). 803–814. 342 indexed citations
15.
Vilar, Eduardo, Maurizio Scaltriti, Judith Balmañà, et al.. (2008). Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines. British Journal of Cancer. 99(10). 1607–1612. 65 indexed citations
16.
Scaltriti, Maurizio, Federico Rojo, Alberto Ocaña, et al.. (2007). Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer. JNCI Journal of the National Cancer Institute. 99(8). 628–638. 659 indexed citations breakdown →
17.
Cosimo, Serena Di, Maurizio Scaltriti, Federico Rojo, et al.. (2007). The PI3-K/AKT/mTOR pathway as a target for breast cancer therapy. Journal of Clinical Oncology. 25(18_suppl). 3511–3511. 19 indexed citations
18.
Vilar, Eduardo, Maurizio Scaltriti, Cristina Saura, et al.. (2007). Microsatellite instability (MSI) due to mutation or epigenetic silencing is associated with increased cytotoxicity to irinotecan (CPT-11) in human colorectal cancer (CRC) cell lines. Journal of Clinical Oncology. 25(18_suppl). 10527–10527. 4 indexed citations
19.
Cosimo, Serena Di, Joan Seoane, Marta Guzmán, et al.. (2005). Combination of the mammalian target of rapamycin (mTOR) inhibitor everolimus (E) with the insulin like growth factor-1-receptor (IGF-1-R) inhibitor NVP-AEW-541: A mechanistic based anti-tumor strategy. Journal of Clinical Oncology. 23(16_suppl). 3112–3112. 13 indexed citations
20.
Anido, Judit, Pablo Matar, Joan Albanell, et al.. (2003). ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.. PubMed. 9(4). 1274–83. 213 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Youngchul Song Breakdown of academic impact, for papers by Teemu T. Junttila Breakdown of academic impact, for papers by Bassam Abdulkarim Breakdown of academic impact, for papers by Marzia Capelletti Breakdown of academic impact, for papers by Violeta Sánchez Breakdown of academic impact, for papers by Muralidhar Beeram Breakdown of academic impact, for papers by Cammie Rinehart Breakdown of academic impact, for papers by Stacy L. Moulder Breakdown of academic impact, for papers by Judy Dering Breakdown of academic impact, for papers by Ludmila Prudkin
Rankless by CCL
2026